BCAB BioAtla Inc.

Biotech Analyst Ratings

Latest News

1. 04 May 2022 BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress

   – Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma –
   

   – Mecbotamab vedotin (BA3011) Phase 2 interim analysis in NSCLC anticipated in first half 2022; interim update projected on 2Q22 earnings call –

   – Ozuriftamab vedotin (BA3021) NSCLC Phase 2 preliminary cohort enrollment completion and interim update anticipated in second half of 2022 –

   – Ozuriftamab vedotin (BA3021) SCCHN Phase 2 and BA3071 Phase 1 studies anticipate first patients dosed in second quarter of 2022 –

   – Cash balance of $219.4 million at quarter-end expected to provide funding into the second half of 2024 –

   – Management to host conference call and webcast today at 4:30 PM Eastern Time –

   SAN DIEGO, May 04, 2022…

   View Full Article
2. 08 April 2022 BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022

   SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial results for the quarter ended March 31, 2022, and provide an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071).
   

   Conference Call and Webcast Information
   Date: May 4, 2022
   Time: 4:30 p.m. ET
   Webcast Link…

   View Full Article
3. 01 March 2022 BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS

   View Full Article
4. 10 January 2022 BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors

   View Full Article
5. 21 December 2021 BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

   SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceutical businesses complements the notable skills and experience…

   View Full Article